Grant: CLEVELAND BIOLABS, INC.
CLEVELAND BIOLABS, INC.
CDFA Program Title
Trans-NIH Recovery Act Research Support
The severity of radiation injury in humans is largely determined by high sensitivity of the gastrointestinal (GI) tract, yet no drugs are approved for this indication. This award is focused on a novel, clinical-stage drug candidate, Protectan CBLB502, a T